Tandem Diabetes Care, Inc. TNDM
- Market cap
- $1.1B
- P/E
- 0.0×
Follow TNDM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.00 | 2.15 | 2.14 | 32.00 | 43.69 | 76.19 | 33.52 | 13.82 | 21.85 | 9.98 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 118.00 | 30.00 | 52.55 | 74.81 | 123.74 | 155.86 | 150.64 | 47.18 | 53.69 | 38.28 |
High Price
|
|||
| 591 | 574 | 653 | 1,043 | 1,500 | 2,000 | 2,600 | 2,400 | 2,650 | 2,500 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 84 | 108 | 184 | 362 | 499 | 703 | 801 | 748 | 940 | 1,015 |
Revenue
|
|||
| 28.00% | 40.98% | 48.85% | 53.60% | 52.23% | 53.53% | 51.54% | 49.17% | 52.07% | 53.81% |
Gross Margin
|
|||
| (83) | (73) | (123) | (25) | (36) | 16 | (93) | (220) | (92) | (200) |
EBT
|
|||
| (99.07%) | (67.87%) | (66.66%) | (6.79%) | (7.27%) | 2.26% | (11.59%) | (29.46%) | (9.77%) | (19.74%) |
EBT Margin
|
|||
| (83) | (73) | (123) | (25) | (34) | 16 | (95) | (223) | (96) | (205) |
Net Income
|
|||
| 5 | 7 | 8 | 6 | 19 | 16 | 20 | 22 | 16 | 16 |
Depreciation
|
|||
| 27.56 | 18.95 | 3.82 | 6.19 | 8.18 | 11.16 | 12.49 | 11.51 | 14.37 | 15.08 |
Revenue/Sh
|
|||
| (27.30) | (12.87) | (2.55) | (0.42) | (0.56) | 0.25 | (1.47) | (3.43) | (1.47) | (3.04) |
Earnings/Sh
|
|||
| (20.01) | (11.65) | (0.17) | 0.72 | 0.40 | 1.77 | 0.79 | (0.49) | 0.37 | (0.14) |
Cash Flow/Sh
|
|||
| (2.92) | (1.01) | (0.06) | (0.33) | (0.53) | (0.37) | (0.67) | (0.79) | (1.00) | (0.30) |
Capex/Sh
|
|||
| (22.93) | (12.66) | (0.23) | 0.38 | (0.12) | 1.39 | 0.12 | (1.28) | (0.63) | (0.44) |
Free CF/Sh
|
|||
| (1.94) | (5.13) | 2.73 | 3.33 | 6.01 | 6.87 | 6.86 | 4.83 | 4.02 | 2.31 |
Book Value/Sh
|
|||
| 3 | 6 | 48 | 59 | 61 | 63 | 64 | 65 | 65 | 67 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 627.17 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.76 | 0.13 | 9.94 | 9.63 | 11.70 | 13.49 | 3.57 | 2.46 | 2.51 | 1.46 |
PS Ratio
|
|||
| 0.00 | 0.00 | 13.92 | 17.89 | 15.93 | 21.89 | 6.50 | 5.87 | 8.96 | 9.53 |
PB Ratio
|
|||
| 1.04 | 0.71 | 9.66 | 9.18 | 11.13 | 13.01 | 3.15 | 2.22 | 2.37 | 1.47 |
EV/Sales
|
|||
| (1.25) | (1.07) | (156.04) | 149.17 | (728.34) | 104.05 | 336.09 | (19.87) | (34.69) | (15.13) |
EV/FCF
|
|||
| (61) | (66) | (8) | 42 | 25 | 111 | 50 | (32) | 24 | (10) |
Op' Cash Flow
|
|||
| (9) | (6) | (3) | (20) | (32) | (24) | (43) | (52) | (66) | (20) |
Capex
|
|||
| (70) | (72) | (11) | 22 | (8) | 88 | 8 | (83) | (41) | (30) |
FCF
|
|||
| 61 | 28 | 122 | 177 | 533 | 680 | 685 | 553 | 477 | 375 |
Working Cap'
|
|||
| 79 | 77 | — | 14 | 203 | 281 | 283 | 285 | 308 | 310 |
Total Debt
|
|||
| 23 | 62 | (129) | (162) | (282) | (342) | (334) | (183) | (130) | 17 |
Net Debt
|
|||
| (6) | (29) | 131 | 195 | 366 | 433 | 440 | 314 | 263 | 155 |
Sh' Equity
|
|||
| (70.38%) | (70.31%) | (81.30%) | (9.30%) | (6.60%) | 1.92% | (9.66%) | (22.20%) | (10.00%) | (22.15%) |
ROA
|
|||
| (278.83%) | (118.44%) | (1,240.85%) | (32.14%) | (5.90%) | 15.60% | (54.60%) | (111.48%) | (46.57%) | (67.83%) |
ROIC
|
|||
| (290.04%) | 416.44% | (240.11%) | (15.17%) | (12.25%) | 3.89% | (21.67%) | (59.08%) | (33.30%) | (97.88%) |
ROE
|
|||
Tandem Diabetes Care, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ENOV Enovis Corporation | $1.1B | 0.0× | Compare |
| IRMD iRadimed Corporation | $1.1B | 47.1× | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | 0.0× | Compare |
| AORT Artivion, Inc. | $1.1B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BVS Bioventus Inc. | $1.1B | 17.0× | Compare |
| BBNX Beta Bionics, Inc. | $1.2B | 0.0× | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $949.2M | 0.0× | Compare |
| CBLL CeriBell, Inc. | $914.2M | 0.0× | Compare |
Tandem Diabetes Care, Inc. (TNDM) key facts
- Tandem Diabetes Care, Inc. (TNDM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024.
- Tandem Diabetes Care, Inc. reported a net loss of $204.7 million, or a loss of $3.04 per share, for fiscal 2025.
- As of September 25, 2026, TNDM traded at $15.72, a market capitalization of $1.1 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 1.0× sales.
- Return on equity was −97.9% and debt-to-equity 4.62.
Tandem Diabetes Care, Inc. (TNDM) Latest News
1 Sep
MiniMed submits new patch pump for FDA clearance, introducing potential competition to Tandem Diabetes Care in the insulin delivery device market. Competitor regulatory filing may moderately influence Tandem's market position and product strategy.
25 Aug
PODD beat Q2 expectations but reset 2026 guidance, prompting questions on ability to sustain growth in diabetes care amid competition including TNDM. PODD guidance reset and earnings beat alters competitive dynamics and investor views in insulin pump sector shared with TNDM.
18 Aug
Tandem Diabetes Care outlines growth strategy via pharmacy distribution shift and tubeless Mobi insulin pump launch. Pharmacy channel expansion and tubeless Mobi product launch constitute major strategic and innovation moves likely to alter trajectory.
15 Aug
Tandem Diabetes Care's Q2 earnings call featured five key analyst questions on operational metrics, product strategy, competitive positioning, and financial guidance. Q2 earnings call questions surface analyst scrutiny of core financials and strategy that can moderately shape near-term investor views.
13 Aug
Tandem Diabetes Care (TNDM) held its Q2 2026 earnings call. Q2 2026 earnings call delivers financial results and outlook that can shift company trajectory and investor views.
11 Aug
TNDM shares rose after the company reported stronger-than-expected quarterly results and raised its full-year revenue outlook, driven by continued growth in its insulin pump sales and improved gross margins. Higher revenue guidance and pump demand growth can lift near-term financial results and sentiment but are unlikely to reshape long-term competitive position.
9 Aug
Tandem Diabetes Care posted Q2 gains in the pharmacy channel along with pipeline execution progress and margin recovery. Q2 channel gains, pipeline advances, and margin recovery indicate moderate effects on operations and positioning.
8 Aug
Tandem Diabetes Care reports record Q2 sales driven by PayGo momentum, lifting TNDM shares 14.8%. Record Q2 sales and PayGo momentum signal strong growth that can shift TNDM trajectory and sentiment.
7 Aug
Tandem Diabetes Care, Inc. released its Q2 2026 earnings call summary covering financial results, operational updates, and outlook for the diabetes care company. Q2 earnings call delivers key financial metrics and strategic updates that typically move stock price and investor outlook.
Tandem Diabetes Care Q2 earnings call covers financial results, revenue figures, operational updates and forward guidance for the diabetes care company. Quarterly earnings data and guidance directly shape near-term investor views and trading activity for TNDM.
6 Aug
Tandem Diabetes Care posted a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall signal weaker financial results with moderate effects on near-term performance.
Tandem Diabetes Care reported Q2 earnings with analysis of key metrics. Q2 earnings disclosure and metrics review can moderately affect financial outlook and investor sentiment.
Tandem Diabetes Care, Inc. released second quarter 2026 financial results. Quarterly earnings releases reveal performance metrics that shape near-term investor views without guaranteeing major strategic shifts.
17 Jul
Tandem Diabetes Care (TNDM) is positioned as the unprofitable stock with exciting potential while two other unnamed stocks face operational or market challenges. TNDM receives positive framing around future potential that may moderately influence short-term investor sentiment.
16 Jul
Tandem Diabetes Care reported Q1 earnings, analyzed against other healthcare technology stocks for comparative market context and sector positioning. Q1 earnings results may moderately shift investor views on Tandem Diabetes Care financials and near-term valuation.
11 Jul
Tandem Diabetes Care integrates Libre 3 Plus to expand device interoperability edge and reinforce positive investment outlook for TNDM. Libre 3 Plus integration strengthens Tandem's competitive positioning via expanded device compatibility.
Tandem Diabetes Care integrates Abbott Libre 3 Plus, prompting evaluation of whether TNDM shares are undervalued after the expansion. Abbott Libre 3 Plus integration delivers moderate competitive gains in diabetes tech but leaves overall trajectory largely unchanged.
10 Jul
DXCM posted growth but its stock stayed flat, pointing to possible mispricing or overlooked factors with direct implications for TNDM valuation and positioning in diabetes technology. Direct comparison to DXCM performance signals moderate pressure on TNDM market perception and competitive stance without major operational shifts.
9 Jul
TNDM highlighted as one Wall Street favorite stock with exciting potential while two others are recommended to avoid. Positive labeling of TNDM as favorite stock with exciting potential can lift near-term investor interest and share price.
7 Jul
Tandem Diabetes Care faces transition risks that the market may be underestimating, with potential effects on its business trajectory and investor views. Transition risks could moderately influence Tandem Diabetes Care financial performance and competitive positioning without guaranteed fundamental change.
1 Jul
Tandem Diabetes Care launches t:slim X2 insulin pump compatibility with Abbott FreeStyle Libre 3 Plus sensor in five international markets. International sensor compatibility launch expands product reach and may lift adoption without major domestic or transformative effects.
30 Jun
Tandem Diabetes Care shares declined on investor concerns over company performance and market conditions. Stock decline signals moderate short-term pressure on operations and sentiment without altering long-term trajectory.
16 Jun
Tandem Diabetes Care (TNDM) released Q1 earnings, prompting analysis of whether investors should buy, sell, or hold the stock. Q1 earnings and related investment analysis can moderately influence TNDM stock sentiment and near-term trading.
5 Jun
Tandem Diabetes Care automated insulin delivery systems received CE Mark for Type 2 diabetes and Type 1 diabetes during pregnancy. CE Mark expands TNDM addressable market to Type 2 and pregnancy indications across Europe.
3 Jun
Wells Fargo upgraded Tandem Diabetes Care citing shifts to pharmacy distribution and insulin pump focus as key growth drivers. Analyst upgrade on pharmacy and pump strategy shifts may lift near-term sentiment without altering core trajectory.
2 Jun
Tandem Diabetes Care plans a 2026 reset that will reshape operations and strategy for TNDM stock. A 2026 reset signals a strategic shift likely to moderately affect financial performance and market positioning.
1 Jun
Tandem Diabetes Care (TNDM) stock rises sharply today on positive developments. Stock price surge signals improved near-term investor sentiment without indicating fundamental long-term shifts.
23 May
Tandem Diabetes Care (TNDM) shares rose 16.7% after the company beat Q3 expectations and reaffirmed its 2025 EBITDA target. Earnings beat and reaffirmed guidance produced a short-term stock gain without evidence of fundamental trajectory change.
18 May
Tandem Diabetes Care held its Q1 earnings call and addressed the top five questions from analysts on financial results, operations, and outlook. Q1 earnings details and analyst questions can moderately affect investor views on Tandem Diabetes Care's near-term performance.
14 May
TNDM stock declined after Q1 earnings and revenue beat expectations, with gross margins improving. Q1 earnings and revenue beat plus gross margin improvement signals moderate positive effect on financial performance despite stock drop.